IP Library Granted Patent US 12,653,599
Granted Patent B2
US 12,653,599 · App. 17/906,965 · Granted Jun 16, 2026

Multi-modality ablation catheter having a shape memory stylet

Inventors: Alexei V. Babkin (Dana Point, CA); Shirzad Shahriari (Laguna Hills, CA); Hou Man Chong (La Palma, CA); Pedram Nourian (Tustin, CA); Faysal S. Ahmed (Irvine, CA); Kevin D. Rupp (Irvine, CA)
Assignee: ADAGIO MEDICAL, INC.
A61B18/02A61B18/0218A61B18/1206A61B18/1477A61B18/1492A61B2017/00867A61B2018/00011A61B2018/00077A61B2018/00166A61B2018/00178A61B2018/00351A61B2018/00577A61B2018/00613A61B2018/00648A61B2018/00714A61B2018/00761A61B2018/00767A61B2018/00791A61B2018/00839A61B2018/00994A61B2018/0212A61B2018/0262A61B2018/1253A61B2018/126A61B2018/1467A61B2218/002A61B2560/0266A61M25/0102A61M25/0158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,599
App. No.
17/906,965
Granted
Jun 16, 2026
Kind
B2
Abstract

A multimodality or hybrid ablation system includes an ablation apparatus for creating a lesion in target tissue. The ablation apparatus has an ablation shaft including a handle, a first portion, an ablation portion, distal tip, at least one ablation energy delivery lumen, at least one ablation energy return lumen, and a stylet lumen that extends substantially along a length of the ablation shaft from the handle to at least the ablation portion. The ablation apparatus also includes a stylet that is capable of being inserted into the stylet lumen where the stylet is made of a shape-memory material. A plurality of electrodes are arranged on the ablation portion for measuring or verifying tissue contact with the tissue and applying a pulsed electric field. Optionally, the pulsed electric field may be applied after or in parallel with freezing the target tissue.

Claims (44)

1 . A multimodality ablation system for creating a lesion in target tissue, the system comprising:

a catheter, said catheter comprising:

a freezing portion;

at least one cryogen delivery lumen;

at least one cryogen return lumen; and

a plurality of therapeutic electrodes configured to deliver pulsed field ablation energy and measure tissue contact information, said therapeutic electrodes disposed directly on an exterior surface of the freezing portion; and

a generator framework operable with the plurality of electrodes to (a) measure tissue contact information, and (b) create pulsed field of electricity to induce cell death during cryogenic conditions.

2 . The system of claim 1 , wherein the catheter further comprises a stylet lumen that extends substantially along a length of the ablation shaft from the handle to at least the freezing portion; and a stylet capable of being inserted into the stylet lumen, the stylet comprising a pre-set shape.

3 . The system of claim 2 , further comprising a cryogen controller operable to circulate a cryogen through the freezing section using the at least one cryogen delivery lumen and the cryogen return lumen.

4 . The system of claim 1 , wherein the generator framework comprises a pulsed field ablation generator operable to create the pulsed field of electricity to induce cell death, and optionally, to measure tissue contact information.

5 . The system of claim 4 , wherein the catheter further comprises a positive charge EP connector for supplying a positive voltage to a first set of the plurality of electrodes and compatible with an EP recording system, and the catheter further comprises a negative charge EP connector for supplying a negative voltage to a second set of the plurality of electrodes and compatible with an EP recording system.

6 . The system of claim 5 , further comprising a PFA adapter cable to electrically couple the positive charge EP connector and the negative charge EP connector to the PFA controller.

7 . A method for treating heart disease by creating at least one lesion in a patient using a multi-modality ablation apparatus, the method comprising:

advancing a distal treatment section of the multi-modality ablation apparatus into the heart, and wherein the multi-modality ablation apparatus comprises a plurality of therapeutic electrodes arranged directly on an exterior surface of the distal treatment section;

manipulating the distal treatment section of the multi-modality ablation apparatus into contact with a first target tissue in which the at least one lesion shall be created;

evaluating tissue contact for a length of continuous contact between the distal treatment section and the first target tissue based on contact information arising from the plurality of electrodes;

optionally adjusting the position of the distal treatment section to increase the length of continuous contact;

selecting at least one ablation modality from the group consisting of cryogenic ablation and pulsed field ablation;

switching the electrodes between tissue contact and ablation modalities via generator switching while maintaining catheter position and tissue contact; and

ablating the first target tissue with the selected at least one ablation modality to create a first lesion, wherein the distal treatment section is operable to perform both cryoablation and pulsed field ablation without requiring catheter exchange or modification; wherein the plurality of electrodes are configured to deliver pulsed field ablation energy and measure tissue contact information, and operable during cryogenic conditions.

8 . The method of claim 7 , wherein the selected at least one ablation modality is pulsed field ablation and cryoablation.

9 . The method of claim 8 , wherein the ablation modalities are performed in sequence on said first target tissue.

10 . The method of claim 7 , wherein the selected at least one ablation modality is based on a tissue type.

11 . A method for creating at least one lesion in a patient using a multi-modality ablation apparatus, the method comprising:

selecting at least one ablation modality from the group consisting of cryo- and pulsed field ablation; and

ablating a first target tissue with the selected at least one ablation modality to create a first lesion;

wherein the selected at least one ablation modality is based on a tissue type; and wherein pulsed field ablation (PFA) is selected for treating myocardium tissue, cryoablation is selected for treating non-myocardium tissue, and a hybrid ablation using both PFA and cryoablation is selected for treating a target area comprising myocardial and non-myocardial tissue.

12 . The method of claim 7 , further comprising selecting at least one ablation modality from the group consisting of cryoablation and pulsed field ablation to ablate a second target tissue subsequent to ablating the first target tissue, and ablating the second target tissue.

13 . The method of claim 12 , wherein the ablation modality selected for the second target tissue is not identical to the ablation modality selected for the first target tissue.

14 . The method of claim 13 , wherein the ablation modality selected for the second target tissue is a hybrid ablation including both cryoablation and pulsed field ablation.

15 . The method of claim 8 , wherein the cryoablation comprises creating an ice layer surrounding the treatment portion of the catheter, and the pulsed field ablation is performed subsequent to the cryoablation and comprises applying a voltage through the ice layer to create an electric field in the tissue beyond the ice layer.

16 . The method of claim 15 , wherein the ice layer has a thickness less than or equal to 500 um.

17 . The method of claim 16 , wherein the electric field extends at least 4 mm from a surface of the catheter into the tissue.

18 . The method of claim 15 , wherein the ice layer has a thickness equal to or greater than 3 mm.

19 . The method of claim 18 , wherein the applied electric field is confined to the ice layer.

20 . The system of claim 3 , wherein the pulsed field ablation generator is operable to create an electric field subsequent to forming a layer of ice around the freezing portion of the catheter.

21 . The system of claim 20 , wherein catheter is operable to generate an ice layer having a thickness less than or equal to 500 um.

22 . The system of claim 20 , wherein the pulsed field ablation generator is operable to create an electric field that extends a depth of at least 4 mm from a surface of the freezing portion of the catheter into the tissue.

23 . The system of claim 20 , wherein the pulsed field ablation generator is operable to create the electric field subsequent to forming the layer of ice such that a ratio of the depth of the electric field to ice thickness is at least 100.

24 . The system of claim 20 , wherein the cryoablation controller is operable to limit the duration of cryoablation to less than or equal to 10 s.

25 . The system of claim 1 , wherein the catheter further comprises an irrigation aperture in the distal section for delivering a liquid in the vicinity of the electrodes.

26 . The system of claim 1 , further comprising a modality detection module operable to recognize whether the catheter plugged the PFA generator is configured for PFA-only or PFCA therapy.

27 . The method of claim 7 , further comprising:

automatically determining which electrodes to pulse during pulsed field ablation based on which electrodes have an acceptable measured tissue contact value.

Assignments (2)
SECURITY INTEREST Recorded Aug 6, 2024
From: ADAGIO MEDICAL HOLDINGS, INC.
To: ALLEGRO MANAGEMENT LLC
Reel/Frame 068337/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: BABKIN, ALEXEI V; NOURIAN, PEDRAM; SHAHRIARI, SHIRZAD; AHMED, FAYSAL; CHONG, HOU MAN; RUPP, KEVIN D
To: ADAGIO MEDICAL, INC.
Reel/Frame 062287/0250 →
Continuity (3)
Provisional Application 63137810 · Jan 15, 2021
Provisional Application 63000400 · Mar 26, 2020
Related Publication 20240058047A1 · Feb 22, 2024
References Cited (81)
US 6161543A · Cox et al. · 2000 [cited by applicant]
US 6190382B1 · Ormsby et al. · 2001 [cited by applicant]
US 6941953B2 · Feld et al. · 2005 [cited by applicant]
US 7083612B2 · Littrup et al. · 2006 [cited by applicant]
US 7273479B2 · Littrup et al. · 2007 [cited by applicant]
US 7410484B2 · Littrup et al. · 2008 [cited by applicant]
US 7507233B2 · Littrup et al. · 2009 [cited by applicant]
US 7921657B2 · Littrup et al. · 2011 [cited by applicant]
US 8177780B2 · Cox et al. · 2012 [cited by applicant]
US 8221411B2 · Francischelli et al. · 2012 [cited by applicant]
US 8387402B2 · Littrup et al. · 2013 [cited by applicant]
US 8591503B2 · Littrup et al. · 2013 [cited by applicant]
US 8740891B2 · Babkin et al. · 2014 [cited by applicant]
US 8740892B2 · Babkin et al. · 2014 [cited by applicant]
US 9113911B2 · Sherman · 2015 [cited by applicant]
US 9408656B2 · Littrup et al. · 2016 [cited by applicant]
US 10271893B2 · Stewart et al. · 2019 [cited by applicant]
US 10543032B2 · Babkin · 2020 [cited by applicant]
US 10575156B2 · Shedletsky et al. · 2020 [cited by applicant]
US 10617459B2 · Yu et al. · 2020 [cited by applicant]
US 10952676B2 · Babkin et al. · 2021 [cited by applicant]
US 20030195605A1 · Kovalcheck et al. · 2003 [cited by applicant]
US 20110160514A1 · Long et al. · 2011 [cited by applicant]
US 20120065631A1 · Arless et al. · 2012 [cited by applicant]
US 20120209273A1 · Zaretzka et al. · 2012 [cited by applicant]
US 20130030425A1 · Stewart et al. · 2013 [cited by applicant]
US 20130030472A1 · Stewart et al. · 2013 [cited by applicant]
US 20130110098A1 · Lalonde · 2013 [cited by applicant]
US 20140066913A1 · Sherman · 2014 [cited by applicant]
US 20140088578A1 · Rubinsky et al. · 2014 [cited by applicant]
US 20150018809A1 · Mihalik · 2015 [cited by applicant]
US 20160166310A1 · Stewart · 2016 [cited by examiner]
US 20170035499A1 · Stewart et al. · 2017 [cited by applicant]
US 20170119465A1 · Long et al. · 2017 [cited by applicant]
US 20180028252A1 · Lalonde · 2018 [cited by applicant]
US 20180085160A1 · Viswanathan et al. · 2018 [cited by applicant]
US 20180325577A1 · Martin et al. · 2018 [cited by applicant]
US 20190038334A1 · Schwartz · 2019 [cited by applicant]
US 20190076179A1 · Babkin et al. · 2019 [cited by applicant]
US 20190125422A1 · Babkin et al. · 2019 [cited by applicant]
US 20190223948A1 · Stewart · 2019 [cited by examiner]
US 20190254735A1 · Stewart · 2019 [cited by examiner]
US 20190262056A1 · Yang et al. · 2019 [cited by applicant]
US 20190365451A1 · Jung, Jr. · 2019 [cited by applicant]
US 20210059737A1 · Babkin et al. · 2021 [cited by applicant]
US 20210259765A1 · Narayan · 2021 [cited by applicant]
US 20210307824A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20240058047A1 · Babkin et al. · 2024 [cited by applicant]
CN 107693114A · 2018 [cited by applicant]
EP 2892455B1 · 2015 [cited by applicant]
WO 2012057915A1 · 2012 [cited by applicant]
WO 2013013098A1 · 2013 [cited by applicant]
WO 2013013099A1 · 2013 [cited by applicant]
WO 2013163469A1 · 2013 [cited by applicant]
WO 2013181660A1 · 2013 [cited by applicant]
WO 2015160574A1 · 2015 [cited by applicant]
WO 2017048965A1 · 2017 [cited by applicant]
WO 2019050894A1 · 2019 [cited by applicant]
WO 2019164650A1 · 2019 [cited by applicant]
WO 2020028282A1 · 2020 [cited by applicant]
WO 2021195311A1 · 2021 [cited by applicant]
Barkagan et al. A novel multielectrode catheter for high-density ventricular mapping: electrogram characterization and utility for scar mapping. Online Jan. 2020. Europace. Mar. 1, 2020;22(3):440-449. doi: 10.1093/europ… [cited by applicant]
Bunch TJ, Cutler MJ. Is pulmonary vein isolation still the cornerstone in atrial fibrillation ablation? J Thorac Dis. Feb. 2015;7(2):132-41. [cited by applicant]
Callans DJ, Gerstenfeld EP, Dixit S, et al. Efficacy of repeat pulmonary vein isolation procedures in patients with recurrent atrial fibrillation. J Cardiovasc Electrophysiol 2004;15:1050-5. [cited by applicant]
Daniels CS, Rubinsky B. Cryosurgery with pulsed electric fields. PLoS One. 2011;6(11):e26219. doi: 10.1371/journal.pone.0026219. Epub Nov. 7, 2011. PMID: 22087224; PMCID: PMC3210118. [cited by applicant]
Golberg A, Rubinsky B, A statistical model for multidimensional irreversible electroporation cell death in tissue. Biomed Eng Online. Feb. 26, 2010;9:13. doi: 10.1186/1475-925X-9-13. PMID: 20187951; PMCID: PMC2839970. [cited by applicant]
International Search Report and Written Opinion of the ISA dated Aug. 5, 2021 for PCT/US2021/024046. [cited by applicant]
International Search Report and Written Opinion of the ISA dated Dec. 16, 2022 for PCT/US2022/076874. [cited by applicant]
Kim et al. Linear ablation in addition to circumferential pulmonary vein isolation (Dallas lesion set) does not improve clinical outcome in patients with paroxysmal atrial fibrillation: a prospective randomized study. E… [cited by applicant]
Kowalski M, Grimes MM, Perez FJ, et al. Histopathologic characterization of chronic radiofrequency ablation lesions for pulmonary vein isolation. J Am Coll Cardiol 2012;59:930-8. [cited by applicant]
Mcgann CJ, Kholmovski EG, Oakes RS, et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol 2008;52:1263-71. [cited by applicant]
Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122:2368-77. [cited by applicant]
Ranjan R, Kato R, Zviman MM, et al. Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI. Circ Arrhythm Electrophysiol 2011;4:279-86. [cited by applicant]
Sawhney N, Anousheh R, Chen WC, et al. Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation. Am J Cardiol 2009;104:366-72. [cited by applicant]
Terricabras M, Piccini JP, Verma A., Ablation of persistent atrial fibrillation: Challenges and solutions. J Cardiovasc Electrophysiol. Jul. 2020;31(7):1809-1821. doi: 10.1111/jce.14311. Epub Dec. 18, 2019. PMID: 318288… [cited by applicant]
Verma A, Kilicaslan F, Pisano E, et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005;112:627-35. [cited by applicant]
Extended European Search Report of EP21776726.8 dated Feb. 29, 2024. [cited by applicant]
Office Action of the Canadian patent application No. 3,171,761 issued on Oct. 16, 2024. [cited by applicant]
Office Action of the Canadian patent application No. 3,171,761 issued on Nov. 21, 2023. [cited by applicant]
Extended European Search Report of EP 22877478.2 dated Aug. 6, 2025. [cited by applicant]
Office Action of the Canadian patent application No. 3,171,761 issued on Jul. 23, 2025. [cited by applicant]